News

On March 1, 2022, Jacco Schutte started as the new CEO of MS sherpa. Jacco has more than 15 years of experience in healthcare and management and will fully use his passion for smart digital applications in healthcare for the further growth of MS sherpa.

“Joining MS sherpa, I can continue to build on the future of healthcare. Smart applications based on technology and data offer great potential for keeping healthcare affordable and available. With MS sherpa and the use of digital biomarkers, we are pioneering in this development,” says Jacco Schutte.

“In recent years, the Orikami team has developed and scientifically validated the product. I look forward to further developing MS sherpa together with healthcare professionals and patients and actually implementing it in daily practice.”

Bram den Teuling, CEO Orikami: “With Jacco on board, we have brought in a real entrepreneur who knows healthcare well. His experiences with health insurers and as an RVE manager within the Zuyderland are very valuable in the roll-out and further development of MS sherpa.

Jacco shares our belief that healthcare can be more customized by using data. We are all looking forward to an intensive collaboration.”

What does MS sherpa do?

Sherpa believes that the future of disease management is based on self-control. With our solution, we want to give patients and their professional care team(s) personal insight into the presence and course of symptoms related to MS.

Sherpa is on a mission to support personalized treatment based on real-world data and individual goals.

MS sherpa provides a clinically validated frequent measurement of digital biomarkers* that enables early detection of progression and a personalized treatment regimen. Our solution helps clinicians meet guidelines for monitoring progressive patients.

Our solutions deliver better outcomes and affordable healthcare.